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Abstract
Background: Prostate cancer remains the most common malignancy among elderly men and the
second leading cause of cancer death in the United States. Although several conventional therapies
are currently available, they have a low efficacy and the more effective treatment modalities need
to be established. Interferons (IFNs) are one of such options known as immunotherapy and
demonstrated their antitumor effects on certain cancer types. Yet such antitumor activity should
be improved or potentiated to have the satisfactory outcomes. In fact, combination therapy has been
proposed as an alternative approach and is being underway in human and animal studies.
Accordingly, we studied whether the combination of IFN-α and D-fraction (PDF), a bioactive
mushroom extract, might potentiate anticancer activity of IFN-α in prostate cancer PC-3 cells in
vitro.
Results: Potential effects of recombinant IFN-α2b (0–100,000 IU/ml), PDF (0–1,000 μg/ml), or their
combinations were assessed on the growth of PC-3 cells at 72 h. Cell cycle analysis using a flow
cytometer and Western blot analysis were performed to explore antiproliferative mechanism of
these agents. The dose-dependent study showed that IFN-α2b up to 20,000 (20 K) IU/ml had no
significant effects, but >60% growth reduction was attained ≤50 K IU/ml. Similarly, PDF showed no
effects up to 250 μg/ml but ~65% growth reduction was seen at 1,000 μg/ml. When IFN-α2b and
PDF were combined, a relatively low concentration (10 K IU/ml) of IFN-α2b and PDF (250 μg/ml)
resulted in a ~65% growth reduction. This was accompanied by a G1 cell cycle arrest, indicated by
cell cycle analysis. Western blots also revealed that the G1-specific cell cycle regulators, CDK2,
CDK4, CDK6, cyclin D1, and cyclin E, had been significantly (>60%) down-regulated in IFN/PDF-
treated cells.
Conclusion: The combination of IFN-α2b (10 K IU/ml) and PDF (250 μg/ml) is capable of inducing
a ~65% reduction in PC-3 cell growth. This appears to be due to a synergistic potentiation of two
agents, leading to a G1 cell cycle arrest. Thus, it is conceivable that PDF may potentiate IFN-α2b
activity, improving immunotherapy for prostate cancer.
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Background
Current therapy for prostate cancer (CaP), the most com-
mon malignancy in elderly men in the United States [1],
is directed at exploitation of the androgen-dependent
state of prostatic cancer cells. Various antiandrogens and
leuteinizing hormone-releasing hormone (LHRH) ago-
nists are useful for blocking the availability of androgen to
the cancer cells [2]. However, the efficacy of these drugs is
of limited duration, and patients experience an almost
inevitable progression of their cancers to the fatal andro-
gen-independent state [3]. To develop an alternative
approach for controlling or preventing such disease pro-
gression, it demands in searching for agents/drugs that
could effectively regulate the CaP proliferation.
Interferons (IFNs) are known to trigger multiple cellular
responses including antiviral activity, growth inhibition,
cell differentiation and immunoregulation [4]. Many
studies have also focused on the potential antitumor
effects of IFNs using both in vitro and in vivo cancer models
[5]. For instance, IFNs have been widely used as immuno-
therapy for urological malignancies including prostate,
bladder, and renal carcinomas [6-8]. Compared to chem-
otherapy, less or moderate side effects of IFNs have also
been shown to be beneficial to cancer patients. Some
encouraging data from such IFN monotherapy have been
reported [9], although they are yet somewhat inconsistent
and conflicting. In addition, particularly in clinical CaP
cases, IFN therapy has several drawbacks such as high cost
and repeated administration [6]. These disadvantages
thus limit its use in clinical practice, and further explora-
tion of improved treatment modality, e.g. combination
therapy, is required.
The D-fraction (PDF), the unique proteoglucan extracted
from maitake mushroom (Grifola frondosa), is the acid-
insoluble, alkali-soluble and hot water-extractable frac-
tion [10]. It structurally consists of either β-1,6-linked glu-
can with β-1,3 branches or β-1,3 glucan branched with β-
1,6 glucosides, having a molecular weight of ~1 × 106 dal-
ton [10]. PDF has been commercially available for a vari-
ety of medical and scientific research, and a number of
published and unpublished studies have thus far sug-
gested the immunomodulatory and antitumor activities
of PDF [11-13]. It has been shown in an animal model
that PDF was capable of activating immune-competent
cells such as natural killer cells and cytotoxic T-cells with
a concomitant increase in interleukin-1 production [11],
indicating stimulation of immune responses. A preventive
or inhibitory activity of PDF on carcinogenesis and metas-
tasis has also been demonstrated in mice [12], suggesting
its antitumor activity. Moreover, a chemosensitizing effect
of PDF has been postulated on conventional anticancer
drugs being currently used [13].
Accordingly, we are interested in investigating whether the
combination of IFN-α2b and PDF may have the potenti-
ated growth inhibitory effects on prostatic cancer cells in
vitro. Such studies may provide us with useful information
on the improved efficacy of IFN therapy on prostate can-
cer.
Results
Effects of IFN-α2b or PDF on PC-3 cell growth
To examine the possible effects of individual IFN-α2b or
PDF on PC-3 cell proliferation, cells were cultured with
varying concentrations of IFN-α2b (0–100,000 = 100 K IU/
ml) or PDF (0–1,000 μg/ml) for 72 h. Such a dose-
dependent study showed that IFN-α2b had no apparent
effects up to 20 K IU/ml but induced >60% growth reduc-
tion at 50 K and 100 K IU/ml (Fig. 1A). Similarly, no
effects of PDF was seen up to 250 μg/ml but a marginal
(10–20%) and significant (~65%) growth reduction was
observed at 500 and 1,000 μg/ml, respectively (Fig. 1B).
Thus, these studies demonstrate that both IFN-α2b and
PDF are capable of inhibiting PC-3 cell growth, although
PDF required rather a high concentration (1,000 μg/ml)
to be effective.
Synergistic growth inhibitory effects of IFN-α2b and PDF
To examine whether combinations of IFN-α2b and PDF
may exhibit the enhanced growth inhibitory effects, the
varying concentrations of IFN-α2b and PDF were com-
bined and their effects on PC-3 cell growth were assessed.
Such results showed that combinations of 10 K IU/ml of
IFN-α2b and 100 or 250 μg/ml of PDF resulted in nearly
40% or 65% growth reduction, respectively (Fig. 2). These
enhanced inhibitory effects are most likely attributed to a
synergistic potentiation of two agents, because the given
concentrations of IFN-α2b (10 K IU/ml) and PDF (100 or
250 μg/ml) by itself had no such effects (Fig. 1AB). Thus,
IFN-α2b and PDF appear to work synergistically.
Effects of IFN-α2b, PDF, or their combination on cell cycle
To better understand the underlying mechanism of such a
synergistic growth inhibition induced by the IFN-α2b/PDF
combination, their possible effects on the cell cycle were
explored next. Cells were treated with IFN-α2b (10 K IU/
ml), PDF (250 μg/ml), or their combination for 72 h, and
they were subjected to cell cycle analysis using a flow
cytometer. IFN-α2b or PDF alone had little effects similar
to cell cycle phase distribution in control cells; however,
the IFN-α2b/PDF combination caused an ~63% decrease
in cell number in the S phase with a concomitant 55%
increase in the G1-phase cell population compared to
those in controls (Fig. 3). These results indicate that the
IFN-α2b/PDF combination causes a blockage of cells
entering from the G1  to the S phase, increasing cell
number in the G1 phase. This accumulation of cells in theJournal of Hematology & Oncology 2008, 1:25 http://www.jhoonline.org/content/1/1/25
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Dose-dependent effects of IFN-α 2b or PDF on PC-3 cell growth Figure 1
Dose-dependent effects of IFN-α 2b or PDF on PC-3 cell growth. PC-3 cells were cultured with varying concentrations 
of either IFN-α2b (0–100,000 IU/ml) or PDF (0–1,000 μg/ml) as indicated, and viable cell numbers in IFN-α2b-treated (A) or 
PDF-treated (B) cases were determined at 72 h. All data represent mean ± SD (standard deviation) from three separate exper-
iments (*p < 0.02; **p < 0.08).Journal of Hematology & Oncology 2008, 1:25 http://www.jhoonline.org/content/1/1/25
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G1 phase is known as a G1 cell cycle arrest [14], which fea-
sibly leads to the growth inhibition.
Down-regulation of cell cycle regulators by IFN-α2b/PDF 
combination
To confirm a G1 cell cycle arrest induced by the IFN-α2b
(10 K IU/ml)/PDF (250 μg/ml) combination, we also
examined its effects on the specific cell cycle regulators for
the G1-S phase transition such as CDK2, CDK4, CDK6,
cyclin D1, and cyclin E [14]. After 72-h treatment, cell
lysates were prepared and subjected to Western blot anal-
ysis, as described in Materials and Methods. Cellular
expressions of these cell cycle regulators following IFN-
α2b/PDF treatment were all significantly reduced by >60%
(quantitated by densitometric scanning), compared to
those in controls (Fig. 4). Such a down-regulation of these
cell cycle "promoters" (to be more properly described)
further supports a blockage of G1-S phase transition.
Taken together, these studies are highly suggestive that a
Effects of combinations of IFN-α 2b and PDF on cell growth Figure 2
Effects of combinations of IFN-α 2b and PDF on cell growth. Cells were cultured with varying concentrations of IFN-
α2b/PDF combination for 72 h, and cell growth was assessed by the % of viable cell number relative to that in control (100%). 
Cell growth in control, IFN-α2b (10 K IU/ml)-treated, or IFN-α2b (10 K)/PDF (100 μg/ml)-treated, or IFN-α2b (10 K)/PDF (250)-
treated cells is shown. The data are mean ± SD from three independent experiments (*p < 0.05).Journal of Hematology & Oncology 2008, 1:25 http://www.jhoonline.org/content/1/1/25
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G1 cell cycle arrest is the critical event taking place in the
IFN-α2b/PDF-induced growth inhibition.
Discussion
IFNs belong to the family of cytokines and are capable of
activating a cascade of intracellular pathways that regulate
cell growth/differentiation and also produce antiviral and
immunological responses [4,15]. Particularly, the antitu-
mor potential of IFNs gained a great attention and has
been extensively investigated for over two decades. Some
early studies showed that IFNs had induced regression of
tumors in a significant number of patients with metastatic
Cell cycle analysis Figure 3
Cell cycle analysis. Cells were cultured with IFN-α2b (10 K IU/ml), PDF (250 μg/ml), or their combination for 72 h, and they 
were subjected to cell cycle analysis as described in Materials and Methods. IFN-α2b or PDF alone had little effects on cell cycle 
phase distribution similar to that in control cells. However, the IFN/PDF combination resulted in significant changes (*p < 0.05) 
in cell populations in the G1 and S phases compared to controls, as shown here.Journal of Hematology & Oncology 2008, 1:25 http://www.jhoonline.org/content/1/1/25
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breast cancer, low-grade lymphoma, and multiple mye-
loma [16]. However, the efficacy of IFNs on tumor regres-
sion was also found to vary with cancer types [17], and
some data from specific IFN monotherapy indeed showed
such discrepancy. Moreover, a high cost and repetitive
administration of IFN (monotherapy) somewhat limit its
clinical utility. Accordingly, reducing a cost while improv-
ing the efficacy of IFNs, "combination" therapy has been
proposed and promoted.
In the present study, we explored such combination ther-
apy as an alternative approach for prostate cancer immu-
notherapy; i.e. combination of IFN-α2b and D-fraction
(PDF). Dose-dependent studies showed that IFN-α2b ≥ 50
K IU/ml or PDF at 1,000 μg/ml was capable of inducing
>60% growth reduction in prostate cancer PC-3 cells (Fig.
1). Moreover, a ~65% growth reduction was attained with
the combination of 10 K IU/ml IFN-α2b and 250 μg/ml
PDF (Fig. 2). This augmented growth inhibition results
conceivably from a synergistic potentiation of two agents,
because neither 10 K IU/ml IFN-α2b nor 250 μg/ml PDF
alone has any growth inhibitory activity (Fig. 1). Thus, the
relatively low concentrations of IFN-α2b and PDF when
combined are required for their potentiated antiprolifera-
tive effects. In other words, to attain the same growth
inhibitory effect (~65%) induced by 50 K IU/ml of IFN-
α2b alone, merely "1/5th" (10 K IU/ml) of that IFN-α2b
would be needed when combined with PDF. It is then
plausible that PDF may not only help potentiate IFN-α2b
activity but also help cut the cost down.
We next examined the effects of IFN-α2b/PDF combina-
tion on the cell cycle regulation in order to explore the
growth inhibitory mechanism. Cell cycle analysis revealed
a ~63% decrease in the S-phase cell number with a con-
comitant 55% increase in the G1-phase cell number fol-
lowing the treatment of IFN-α2b/PDF combination (Fig.
3). The resulting "G1 cell accumulation" is termed a G1 cell
cycle arrest, accounting in part for the ultimate growth ces-
sation. In addition, the expressions of specific G1 cell cycle
regulators, such as CDK2, CDK4, CDK6, and cyclins D1/E,
were all markedly (>60%) down-regulated (Fig. 4). Thus,
these findings suggest that the growth inhibitory action of
IFN-α2b/PDF combination may target primarily the G1-S
phase transition in the cell cycle, resulting in a G1 arrest.
Yet, it should be also noted that IFNs are known to mod-
ulate many proteins and enzymes [18], particularly spe-
cific  protein kinases acting on the signal transduction
pathway for cell proliferation and/or differentiation. In
other words, IFNs can regulate cell growth through the sig-
nal transduction mediated by these protein kinases. Addi-
tionally, it has been documented that IFNs could induce
DNA fragmentation, leading to an accumulation of small
or low-molecular-weight DNA [19]. This may imply acti-
vation of a specific protein kinase called double-stranded
DNA-dependent protein kinase (DNA-PK), which
requires small double-stranded DNA for its activation
[20]. DNA-PK is also believed to play an important role in
the cell cycle regulation [21]. These information further
suggest that our IFN-α2b/PDF combination may affect cer-
tain protein kinase(s), triggering the specific cascade
events (via the signal transduction) on the cell cycle to
ultimately cease cancer cell growth. Therefore, such bio-
chemical studies are undoubtedly required and being
underway in our laboratory.
In addition, it is important to further investigate whether
the enhanced growth inhibitory effect of IFN-α2b/PDF
combination observed in this in vitro study might be also
demonstrated in animal study (in vivo). Such study would
Western blot analysis Figure 4
Western blot analysis. After cells were treated with or 
without the combination of IFN-α2b (10 K IU/ml) and PDF 
(250 μg/ml) for 72 h, cell lysates (7 μg) obtained from control 
and the IFN-α2b/PDF-treated cells were analyzed for CDK2, 
CDK4, CDK6, cyclin D1, and cyclin E using Western blots. 
Significantly (>60%) reduced expressions of all these regula-
tors following the IFN/PDF treatment are apparent on the 
blots.Journal of Hematology & Oncology 2008, 1:25 http://www.jhoonline.org/content/1/1/25
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then allow us to assess the actual efficacy of IFN-α2b/PDF
combination on prostate tumor grown in mice and to
determine the effective or tolerable physiological concen-
trations of these agents. This will be conducted shortly as
our Phase II study.
Furthermore, the safety of IFN-α2b or PDF in human use
would be certainly concerned. IFN-α2b has been often
used in immunotherapy for various cancer patients and its
concentrations up to 5 × 106 IU have been shown to be
relatively safe and tolerable in those with prostate cancer
[9,22]. It eventually needs to be determined how the effec-
tive concentration of 10 K IU/ml IFN-α2b (in combination
with PDF) in this study would be extrapolated to actual
patients. For PDF, early animal and clinical studies ascer-
tained the safety of PDF without any side/adverse effects
[13]. This was further supported by the fact that the U.S.
Food and Drug Administration (FDA) had exempted D-
fraction from a Phase I toxicology study. The FDA has also
approved PDF for an Investigational New Drug (IND)
application to conduct a Phase II pilot study on patients
with advanced breast and prostate cancer [23]. Although
such clinical trials are currently in progress, the effective
concentrations of PDF yet remain to be established. Taken
together, our next animal study is crucial and indisputably
required for confirming the safety of IFN-α2b and PDF and
also obtaining valid information on their effective and
tolerable physiological concentrations. It may then help
lead us to an ultimate clinical trial in the future.
Conclusion
In summary, the combination of IFN-α2b and PDF dem-
onstrates a synergistic antiproliferative activity on prostate
cancer PC-3 cells. This potentiated growth inhibition
results primarily from a G1 cell cycle arrest. Therefore, the
low-dose IFN-α2b/PDF combination may provide an alter-
native, improved immunotherapy for prostate cancer,
implying its clinical utility/application. It is promising but
further studies are yet required.
Methods
Cell culture
The human prostate cancer PC-3 cells, derived from a
patient with bone metastasis, were obtained from the
American Type Culture Collection (Rockville, MD). Cells
were maintained in RPMI-1640 medium containing 10%
fetal bovine serum, penicillin (100 U/ml), and streptomy-
cin (100 μg/ml). Routinely, culture medium was changed
every 3 to 4 days and the passage of cells was performed
weekly. For experiments, cells were seeded in T-75 flasks
or 6-well culture plates at the initial cell density of 1 × 105
cells/ml and were cultured with recombinant interferon-
α2b (IFN-α2b; Schering Corp., Kenilworth, NJ), D-fraction
(PDF; Maitake Products, Inc., Paramus, NJ) or their com-
binations. Cell numbers were then assessed at specified
times using the trypan blue exclusion method.
Cell cycle analysis
A FACScan flow cytometer (Becton-Dickinson, San Jose,
CA), equipped with a double discrimination module, was
employed for cell cycle analysis. Approximately 1 × 106
cells were resuspended in 500 μl of propidium iodide
solution (20 μg/ml propidium iodide, 0.2 mg/ml RNase,
0.2 mg/ml EDTA, 0.5% NP-40) and incubated at room
temperature for 1 h. Ten thousand nuclei were analyzed
for each sample, and CellFit software was used to quantify
cell cycle compartments and estimate cell cycle phase frac-
tions.
Western blot analysis
Cell pellets from control and IFN-α2b/PDF-treated cells
were resuspended in cell lysis buffer and cell lysates were
prepared by freeze-thaw three times in liquid nitrogen.
The Western blot procedure essentially followed the pro-
tocol described previously [24]. Briefly, an equal amount
of proteins (7 μg) from control and IFN-α2b/PDF-treated
cell lysates was resolved by 10% SDS-PAGE (SDS-polyacr-
ylamide gel electrophoresis) and transferred to a nitrocel-
lulose membrane. The blot was first incubated for 90 min
with the primary antibodies against CDK2, CDK4, CDK6,
cyclin D1, or cyclin E (Santa Cruz Biotechnology, Santa
Cruz, CA), followed by incubation with the appropriate
secondary antibody conjugates for 30 min. The specific
immunoreactive proteins were then detected by chemilu-
minescence, following a vender's protocol (Kirkegaard
and Perry Laboratories, Gaithersburg, MD), and quanti-
fied using a scan densitometer (Silk Scientific, Oregon,
UT).
Statistical analysis
All data are presented as the mean ± SD (standard devia-
tion), and statistical differences between groups were
assessed with the unpaired Student's t test. A value of p <
0.05 is considered to be significant.
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